Issue Date: May 1, 2023
Issued by: Center for Drug Evaluation and Research
Topic(s): Clinical – Medical, Pediatric Product Development
Status: Final
Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled “Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products; Guidance for Industry.” The document provides guidance to assist sponsors in the clinical development of nicotine replacement therapy (NRT) drug products, including but not limited to those intended for smoking cessation and related chronic indications. This guidance finalizes the draft guidance of the same title issued on February 22, 2019.
Download the Guidance Document
